Tumour-targeting MRI contrast developed, based on human protein

Google+ Pinterest LinkedIn Tumblr +

A Massachusetts Medical School team led by Gang Han, PhD, has designed a human protein-based, tumour-targeting Magnetic Resonance Imaging (MRI) contrast that can be easily cleared by the body.

The discovery holds promise for clinical application, including early stage tumour detection because of the enhanced MRI contrast, according to Dr. Han, associate professor of biochemistry & molecular pharmacology at University of Massachusetts Medical School.

MRI is one of the most widely used, noninvasive and versatile imaging tools for clinical detection, staging and monitoring of malignancy, without the need for ionizing radiation or harmful radionuclides.

The most frequently employed contrast agents used in MRI are gadolinium (Gd)-based, since they do not provoke an immune response in cells. However, such compounds require high doses of intravenous administration and are retained in the body’s organs.

In the search for alternative, Han and colleagues focused on proteins, which are naturally occurring nanomaterials. For example, the protein-bound nanoparticle Abraxane can be used to treat metastatic breast cancer. In the same way, protein scaffolds that encapsulate metal-based nanoparticulate contrast agents also appear to enhance the effectiveness of contrast agents.

In a paper published June 26 in Nano Letters, ACS Publications, Han and colleagues outlined how human transferrin (Tf) proteins can be used to create an MRI contrast nanoprobe by mimicking the natural process to form special nanoparticles called gadolinium biomineralized human transferrin protein-based nanoparticles or Gd@TfNP.

“The Gd@TfNPs preserve the functions of Tf very well, possess superior chemical and physical properties, and are brighter compared to the Gd-based agents currently in use,” Han said, adding that the nanoparticles could also be used as tumour-targeting and systematically clearable contrast agents for MR detection of early-stage tumours.

“Such probes can immediately leave the tumour sites after delivery and we could track the overall process by MRI. Such a technique might be useful not only for visualizing tumour therapies, but for optimizing drug dose and evaluating clinical results,” said Yang Zhao, MD, PhD, of the Second Hospital of Tianjin Medical University and the paper’s first author.


Paper: Yang Zhao, Jing Peng, Jingjin Li, Ling Huang, Jinyi Yang, Kai Huang, Hewen Li, Ning Jiang, Shaokuan Zheng, Xuening Zhang, Yuanjie Niu, Gang Han. Tumor-Targeted and Clearable Human Protein-Based MRI Nanoprobes. Nano Letters, 2017; DOI: 10.1021/acs.nanolett.7b00828

Source: University of Massachusetts Medical School

Share.

About Author

ONA Editor

The ONA Editor curates oncology news, views and reviews from Australia and around the world for our readers. In aggregated content, original sources will be acknowledged in the article footer.

Leave A Reply